Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. NVDA
2. SPCX
3. ACN
4. MU
5. APGE
6. MSTR
7. HOOD
8. ABBV
9. DFTX
10. RGNX

Go back to Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.05 -0.04 (0.4%)
Previous Close $10.09    52 Week High $2.18 
Open $10.47    52 Week Low $0.30 
Day High $10.47    P/E N/A 
Day Low $10.02    EPS $-3.32 
Volume 30,391       

TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.05 -0.04 (0.4%)
Previous Close $10.09    52 Week High $2.18 
Open $10.47    52 Week Low $0.30 
Day High $10.47    P/E N/A 
Day Low $10.02    EPS $-3.32 
Volume 30,391